Strong quarter from Inogen helps stock climb double digits
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The Trade Desk shares gain back 12% loss in week after earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind keeps hitting higher revenues
Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, announced that revenue for the quarter ended Sept. 30 hit $70.1 million, up from $51.2 Read More →
Olaplex’s struggles continue as earnings miss estimates
Montecito-based Olaplex missed analyst expectations in both revenue and net income when it announced its earnings for the third quarter of 2024. Announced Nov. 7, Olaplex noted that sales decreased 3.6% to $119.1 million in the third quarter of 2024.As a result, net income decreased 27.3% to $14.7 million and adjusted net income decreased 13.8% Read More →
Procore cuts down on losses, keeps growing sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Deckers, Hoka continue leading the footwear pack
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen, investors focused on obesity drug candidate
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
